Literature DB >> 1859491

Long-term colchicine treatment in children with familial Mediterranean fever.

D Zemer1, A Livneh, Y L Danon, M Pras, E Sohar.   

Abstract

Three hundred fifty children (younger than age 16) who had familial Mediterranean fever (FMF) were given continuous prophylactic treatment with colchicine (1-2 mg/day) for 6-13 years. Complete remission of febrile attacks was achieved in 64% of the patients, and partial remission in 31%. Protracted attacks of arthritis virtually disappeared. None of the children developed amyloidosis while on the colchicine regimen. Side effects of colchicine were insignificant, and did not prompt permanent discontinuation of treatment in any of the children. Their growth, development, and subsequent fertility were normal. The efficacy of long-term colchicine treatment of children with FMF makes early diagnosis life saving.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1859491     DOI: 10.1002/art.1780340806

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  42 in total

1.  Genetic linkage study of familial Mediterranean fever (FMF) to 16p13.3 and evidence for genetic heterogeneity in the Turkish population.

Authors:  A N Akarsu; U Saatci; S Ozen; A Bakkaloglu; N Besbas; M Sarfarazi
Journal:  J Med Genet       Date:  1997-07       Impact factor: 6.318

Review 2.  Reactive amyloidosis.

Authors:  J David; P Woo
Journal:  Arch Dis Child       Date:  1992-03       Impact factor: 3.791

3.  Risk factors for subclinical inflammation in children with Familial Mediterranean fever.

Authors:  Meral Torun Bayram; Tufan Çankaya; Elçin Bora; Salih Kavukçu; Ayfer Ülgenalp; Alper Soylu; Mehmet Türkmen
Journal:  Rheumatol Int       Date:  2015-02-11       Impact factor: 2.631

Review 4.  Autoinflammation: translating mechanism to therapy.

Authors:  Taylor A Doherty; Susannah D Brydges; Hal M Hoffman
Journal:  J Leukoc Biol       Date:  2011-02-17       Impact factor: 4.962

Review 5.  The role of plant-derived drugs and herbal medicines in healthcare.

Authors:  P A De Smet
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

6.  Different pharmaceutical preparations of colchicine for Familial Mediterranean Fever: are they the same?

Authors:  Hakan Emmungil; Ufuk İlgen; Sezin Turan; Samet Yaman; Orhan Küçükşahin
Journal:  Rheumatol Int       Date:  2019-08-28       Impact factor: 2.631

7.  The effect of colchicine and disease severity on physical growth in children with familial Mediterranean fever.

Authors:  Tuba Çelen Yoldaş; Nilgün Çakar; Özge Başaran; Banu Acar; Nermin Uncu; F Şemsa Çaycı
Journal:  Clin Rheumatol       Date:  2015-09-18       Impact factor: 2.980

8.  A non-peptide NK1-receptor antagonist, RP 67580, inhibits neurogenic inflammation postsynaptically.

Authors:  S M Moussaoui; F Montier; A Carruette; J C Blanchard; P M Laduron; C Garret
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

Review 9.  Therapy of autoinflammatory syndromes.

Authors:  Hal M Hoffman
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

10.  The effect of colchicine on physical growth in children with familial mediterranean fever.

Authors:  Z Birsin Ozçakar; Gülsüm Kadioğlu; Zeynep Siklar; Asli Kavaz; F Nur Aksanal; Merih Berberoğlu; Mesiha Ekim; Gönül Ocal; Fatoş Yalçinkaya
Journal:  Eur J Pediatr       Date:  2009-12-17       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.